You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHMPL-004
Accession NumberDB05767
TypeSmall Molecule
GroupsInvestigational
DescriptionHMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII410105JHGR
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationInvestigated for use/treatment in ulcerative colitis.
PharmacodynamicsNot Available
Mechanism of actionHMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-α, IL-1β and IL-6. HMPL-004 was demonstrated to inhibit TNF-α and IL-1β production in cell-based assays. HMPL-004 is also able to inhibit NF-kB activation. NF-kB is a family of transcriptional factors that regulate a wide spectrum of genes critically involved in host defence and inflammation. The mechanism of action of HMPL-004 was further supported in laboratory IBD animal models. Treatment of IBD rats with HMPL-004 caused a significant drop in plasma cytokine concentrations, including TNF-α and IL-1β.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabHMPL-004 may increase the anticoagulant activities of Abciximab.
AcebutololHMPL-004 may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Aceclofenac.
AcenocoumarolHMPL-004 may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with HMPL-004.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with HMPL-004.
Alendronic acidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Alendronic acid.
AliskirenHMPL-004 may decrease the antihypertensive activities of Aliskiren.
AlprenololHMPL-004 may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with HMPL-004.
AmikacinHMPL-004 may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideHMPL-004 may decrease the antihypertensive activities of Amiloride.
AncrodHMPL-004 may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with HMPL-004.
Antithrombin III humanHMPL-004 may increase the anticoagulant activities of Antithrombin III human.
ApixabanHMPL-004 may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with HMPL-004.
ArdeparinHMPL-004 may increase the anticoagulant activities of Ardeparin.
ArgatrobanHMPL-004 may increase the anticoagulant activities of Argatroban.
ArotinololHMPL-004 may decrease the antihypertensive activities of Arotinolol.
AtenololHMPL-004 may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with HMPL-004.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with HMPL-004.
BalsalazideHMPL-004 may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with HMPL-004.
BecaplerminHMPL-004 may increase the anticoagulant activities of Becaplermin.
BefunololHMPL-004 may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with HMPL-004.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with HMPL-004.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with HMPL-004.
BetaxololHMPL-004 may decrease the antihypertensive activities of Betaxolol.
BevantololHMPL-004 may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with HMPL-004.
BisoprololHMPL-004 may decrease the antihypertensive activities of Bisoprolol.
BivalirudinHMPL-004 may increase the anticoagulant activities of Bivalirudin.
BopindololHMPL-004 may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with HMPL-004.
BufuralolHMPL-004 may decrease the antihypertensive activities of Bufuralol.
BumetanideHMPL-004 may decrease the diuretic activities of Bumetanide.
BupranololHMPL-004 may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with HMPL-004.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with HMPL-004.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with HMPL-004.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with HMPL-004.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with HMPL-004.
CarteololHMPL-004 may decrease the antihypertensive activities of Carteolol.
CarvedilolHMPL-004 may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with HMPL-004.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with HMPL-004.
CeliprololHMPL-004 may decrease the antihypertensive activities of Celiprolol.
CertoparinHMPL-004 may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with HMPL-004.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with HMPL-004.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with HMPL-004.
CholestyramineCholestyramine can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with HMPL-004.
Citric AcidHMPL-004 may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with HMPL-004.
ColesevelamColesevelam can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineHMPL-004 may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with D-Limonene.
Dabigatran etexilateHMPL-004 may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinHMPL-004 may increase the anticoagulant activities of Dalteparin.
DanaparoidHMPL-004 may increase the anticoagulant activities of Danaparoid.
DaunorubicinHMPL-004 may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Deferasirox.
DesirudinHMPL-004 may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with HMPL-004.
DextranHMPL-004 may increase the anticoagulant activities of Dextran.
Dextran 40HMPL-004 may increase the anticoagulant activities of Dextran 40.
Dextran 70HMPL-004 may increase the anticoagulant activities of Dextran 70.
Dextran 75HMPL-004 may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with HMPL-004.
DicoumarolHMPL-004 may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with HMPL-004.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with HMPL-004.
DihydrostreptomycinHMPL-004 may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with HMPL-004.
DoxorubicinHMPL-004 may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneHMPL-004 may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Droxicam.
Edetic AcidHMPL-004 may increase the anticoagulant activities of Edetic Acid.
EdoxabanHMPL-004 may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with HMPL-004.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with HMPL-004.
EnoxaparinHMPL-004 may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Epirizole.
EpirubicinHMPL-004 may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneHMPL-004 may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with HMPL-004.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with HMPL-004.
EsmololHMPL-004 may decrease the antihypertensive activities of Esmolol.
Etacrynic acidHMPL-004 may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with HMPL-004.
Ethyl biscoumacetateHMPL-004 may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with HMPL-004.
EtofenamateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with HMPL-004.
Evening primrose oilThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when HMPL-004 is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with HMPL-004.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with HMPL-004.
FlunixinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with HMPL-004.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with HMPL-004.
Fondaparinux sodiumHMPL-004 may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with HMPL-004.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with HMPL-004.
FramycetinHMPL-004 may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideHMPL-004 may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with HMPL-004.
GentamicinHMPL-004 may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Haloperidol.
HeparinHMPL-004 may increase the anticoagulant activities of Heparin.
HirulogHMPL-004 may increase the anticoagulant activities of Hirulog.
HydralazineHMPL-004 may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with HMPL-004.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with HMPL-004.
Hygromycin BHMPL-004 may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with HMPL-004.
IbuproxamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Icatibant.
IdarubicinHMPL-004 may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with HMPL-004.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with HMPL-004.
IndenololHMPL-004 may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with HMPL-004.
IndoprofenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with HMPL-004.
IsoxicamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Isoxicam.
KanamycinHMPL-004 may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with HMPL-004.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with HMPL-004.
LabetalolHMPL-004 may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with HMPL-004.
LepirudinHMPL-004 may increase the anticoagulant activities of Lepirudin.
LevobunololHMPL-004 may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with HMPL-004.
LithiumThe serum concentration of Lithium can be increased when it is combined with HMPL-004.
LornoxicamThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with HMPL-004.
LoxoprofenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with HMPL-004.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with HMPL-004.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HMPL-004.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with HMPL-004.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HMPL-004.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with HMPL-004.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with HMPL-004.
MesalazineHMPL-004 may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with HMPL-004.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with HMPL-004.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with HMPL-004.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with HMPL-004.
MetipranololHMPL-004 may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with HMPL-004.
MetoprololHMPL-004 may decrease the antihypertensive activities of Metoprolol.
MetrizamideHMPL-004 may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with HMPL-004.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with HMPL-004.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with HMPL-004.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HMPL-004.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HMPL-004.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with HMPL-004.
NadololHMPL-004 may decrease the antihypertensive activities of Nadolol.
NadroparinHMPL-004 may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with HMPL-004.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with HMPL-004.
NCX 4016The risk or severity of adverse effects can be increased when HMPL-004 is combined with NCX 4016.
NeomycinHMPL-004 may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Nepafenac.
NetilmicinHMPL-004 may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with HMPL-004.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with HMPL-004.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with HMPL-004.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with HMPL-004.
OlsalazineHMPL-004 may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with HMPL-004.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with HMPL-004.
OrgoteinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Orgotein.
OtamixabanHMPL-004 may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with HMPL-004.
OxprenololHMPL-004 may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HMPL-004.
PamidronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Parecoxib.
ParomomycinHMPL-004 may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololHMPL-004 may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateHMPL-004 may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with HMPL-004.
PhenindioneHMPL-004 may increase the anticoagulant activities of Phenindione.
PhenprocoumonHMPL-004 may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with HMPL-004.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with HMPL-004.
PindololHMPL-004 may decrease the antihypertensive activities of Pindolol.
PiretanideHMPL-004 may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with HMPL-004.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with HMPL-004.
PlicamycinHMPL-004 may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with HMPL-004.
PractololHMPL-004 may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with HMPL-004.
ProbenecidThe serum concentration of HMPL-004 can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Propacetamol.
PropranololHMPL-004 may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with HMPL-004.
Protein CHMPL-004 may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeHMPL-004 may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with HMPL-004.
PuromycinHMPL-004 may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with HMPL-004.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with HMPL-004.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with HMPL-004.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with HMPL-004.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with HMPL-004.
ReviparinHMPL-004 may increase the anticoagulant activities of Reviparin.
RibostamycinHMPL-004 may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Risedronate.
RivaroxabanHMPL-004 may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with HMPL-004.
SalicylamideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with HMPL-004.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with HMPL-004.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with HMPL-004.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with HMPL-004.
SeratrodastThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Seratrodast.
SotalolHMPL-004 may decrease the antihypertensive activities of Sotalol.
SpectinomycinHMPL-004 may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with HMPL-004.
SpironolactoneHMPL-004 may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with HMPL-004.
StreptomycinHMPL-004 may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinHMPL-004 may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineHMPL-004 may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with HMPL-004.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with HMPL-004.
SulodexideHMPL-004 may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with HMPL-004.
TacrolimusHMPL-004 may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with HMPL-004.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with HMPL-004.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with HMPL-004.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with HMPL-004.
TenofovirThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with HMPL-004.
TepoxalinThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with HMPL-004.
TiludronateThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tiludronate.
TimololHMPL-004 may decrease the antihypertensive activities of Timolol.
TobramycinHMPL-004 may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with HMPL-004.
TorasemideHMPL-004 may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with HMPL-004.
TranilastThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with HMPL-004.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with HMPL-004.
TriamtereneHMPL-004 may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with HMPL-004.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with HMPL-004.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with HMPL-004.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with HMPL-004.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with HMPL-004.
WarfarinHMPL-004 may increase the anticoagulant activities of Warfarin.
XimelagatranHMPL-004 may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with HMPL-004.
Zoledronic acidThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with HMPL-004.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein domain specific binding
Specific Function:
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.
Gene Name:
IL1B
Uniprot ID:
P01584
Molecular Weight:
30747.7 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Interleukin-6 receptor binding
Specific Function:
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as ...
Gene Name:
IL6
Uniprot ID:
P05231
Molecular Weight:
23717.965 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB2
Uniprot ID:
Q00653
Molecular Weight:
96748.355 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB1
Uniprot ID:
P19838
Molecular Weight:
105355.175 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24